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Prehospital Administration of Unfractionated Heparin in
ST-Segment Elevation Myocardial Infarction Is Associated
With Improved Long-Term Survival
Christopher McGinley, MBChB,* Ify R Mordi, PhD,*† Paul Kell,‡ Peter Currie, MD,†
Stuart Hutcheon, MD,† Stephan Koch, MD,† Thomas Martin, MD,† and John Irving, MD†
Objective: Administration of unfractionated heparin to STEMI
patients by the ambulance service is an established practice in
Scotland, but the efficacy is unknown. We studied the effects of
unfractionated heparin in STEMI patients treated by primary
percutaneous coronary intervention, on infarct artery patency and
mortality.
Methods and Results: Consecutive patients (n = 1000) admitted
to Ninewells Hospital, Dundee, from 2010 to 2014 for primary per-
cutaneous coronary intervention were allocated to 2 groups: 437
(44%) prehospital heparin (PHH) administered by paramedics, and
563 (56%) in-hospital heparin. A trained medical student assessed
coronary flow at presentation and collected the data. Mortality status
was ascertained at 30 days and 5 years. Cox proportional hazards
regression models were generated. The patient groups were similar,
although PHH had shorter symptom onset-treatment time (187 vs. 251
minutes, P , 0.001) and less cardiogenic shock (3.9% vs. 8.0%, P =
0.008). Initial coronary flow was not different between the groups.
Thirty day mortality in PHH was 2.5% versus 8.3%, P , 0.001.
Independent predictors of 30-day mortality were age (odds ratio 1.07,
95% CI 1.04–1.09), cardiogenic shock (5.97, 3.33–10.69), radial access
(0.53, 0.28–0.98), and PHH (0.33, 0.17–0.66). Five-year mortality in
PHH was 13.0% versus 21.6%, P , 0.001. Significant predictors of
long-term mortality were age (1.07, 1.06–1.09), cardiogenic shock
(3.40, 2.23–5.17), and PHH (0.68, 0.49–0.96).
Conclusions: PHH was associated with reduced short- and long-
term mortality after adjusting for important potential confounders.
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INTRODUCTION
ST-segment elevation myocardial infarction
(STEMI) is caused by a thrombotic occlusion of a
coronary artery superimposed on a ruptured atheroscle-
rotic plaque. Immediate primary percutaneous coronary
intervention (PPCI) is well established as the optimal
treatment for STEMI because it delivers effective and
sustained reperfusion of the infarcted territory.1–3
Treatment efficacy is greatest when delivered rapidly.4
Not all patients presenting with STEMI have sustained
and complete occlusion of the culprit coronary artery;
when residual coronary flow is present at angiography, it
is associated with better long-term outcomes.5,6 Enhancing
coronary flow before PPCI with prehospital thrombolysis,
a strategy of facilitated PCI, was tested extensively, but
was found to increase bleeding and stroke.7
In the absence of randomized trial data, it is perhaps
surprising that prehospital administration of unfractionated
heparin (UFH) is recommended in many STEMI protocols.
A few retrospective studies have indicated a possible
benefit.8–12 The reasoning is pragmatic: anticoagulation
and antiplatelet therapy are essential for safe PCI, early
administration may lead to improved flow at initial angi-
ography, and thus benefit. The risk of harmful bleeding is
significantly less than with thrombolysis. Heparin is well
established as the ideal antithrombotic for PPCI, with the
randomized HEAT-PPCI trial demonstrating reduced major
adverse ischemic events, expense, and similar bleeding
rates to bivalirduin.13
The aim of this study was to investigate the effects of
prehospital heparin (PHH) on infarct artery patency in STEMI
patients before PPCI. We hypothesized that early administra-
tion of UFH by the Scottish Ambulance Service may improve
IRA patency before PCI. This in turn would be associated
with improved short-term and long-term survival.
METHODS
Population
This retrospective observational study examined
consecutive patients presenting with STEMI, treated with
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PPCI at Ninewells Hospital, Dundee, United Kingdom
between February 2010 and October 2014. The Ninewells
PPCI service covers approximately 500,000 patients from
Tayside, Fife, and Angus. The study was approved by the
local ethics committee.
The indication for PPCI was established in patients with
chest pain and an electrocardiogram showing ST-segment
elevation in 2 or more contiguous leads, with a minimum of
0.1 mV in frontal leads and 0.2 mV in precordial leads or new
left bundle branch block that evolved within 12 hours. ECG
telemetry to the Coronary Care Unit in Ninewells Hospital
assisted prehospital diagnosis.
Patients diagnosed prehospital by the Scottish
Ambulance Service paramedics were treated according
to the national protocol with oral aspirin 300 mg, clopi-
dogrel 300 mg, and 5000 units of UFH administered
intravenously by a paramedic as per standard protocol in
Scotland.
A total of 1000 patients were used in this study. Data
were retrospectively collected from routine databases. All-
cause mortality was ascertained at 30 days and 5 years
post-PPCI from a local patient administration database
(TOPAZ).
Heparin Pretreatment
Patients were classified into the following groups
relative to PHH administration:
1. PHH group: UFH administered before arrival at PCI center
2. In-hospital heparin (IHH) group: UFH administered imme-
diately before PCI.
Thrombolysis in Myocardial Infarction (TIMI)
Flow
A trained medical student assessed coronary artery flow
before PCI. Flow was retrospectively determined using the
TIMI study group grade flow. Patients were classified in
2 groups: TIMI flow 0–1 (coronary artery occluded) and
TIMI flow 2–3 (coronary artery patent). Interobserver and
intraobserver variability was measured after data collection
to determine the reliability of this assessment.
TABLE 1. Baseline Characteristics
Prehospital Heparin Group (PHH), n = 437 IHH Group, n = 563 P
Male sex, n (%) 304 (69.6) 390 (69.3) 0.92
Age, yr 63.7 63.7 0.99
Smoking, n (%) 173 (39.6) 232 (41.2) 0.60
Hypertension, n (%) 132 (30.2) 168 (29.8) 0.89
Diabetes, n (%) 38 (8.7) 53 (9.4) 0.70
Dyslipidaemia, n (%) 90 (20.6) 99 (17.6) 0.22
Family history CAD, n (%) 100 (22.9) 114 (20.2) 0.31
Previous CVA/TIA, n (%) 24 (5.5) 26 (4.6) 0.66
Peripheral vascular disease, n (%) 9 (2.1) 15 (2.7) 0.54
Chronic lung disease, n (%) 26 (5.9) 19 (3.4) 0.05
LVEF , 45, n (%) 71 (16.2) 81 (14.4) 0.42
LVEF (%) 50.74 51.44 0.24
Previous PCI, n (%) 19 (4.3) 42 (7.5) 0.04
Previous CABG, n (%) 7 (1.6) 13 (2.3) 0.43
Radial access, n (%) 397 (90.8) 487 (86.5) 0.03
Duke jeopardy score 3.18 3.43 0.03
Differences between categorical variables were assessed with x2 test. Differences in continuous variables were assessed with the Student’s t-test if normally distributed.
CABG, coronary artery bypass graft; CAD, coronary artery disease; CVA, cerebrovascular accident; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary
intervention; TIA, transient ischemic attack.
TABLE 2. Temporal Delays and Hemodynamic Status
Prehospital Heparin Group (PHH), n = 437 IHH Group, n = 563 P
Mechanical ventilation, n (%) 9 (2.1) 18 (3.2) 0.27
Circulatory support, n (%) 13 (3.0) 41 (7.3) 0.003
Cardiogenic shock, n (%) 17 (3.9) 45 (8.0) 0.008
Temporal intervals
Call time—PPCI time, min 99 127 ,0.001
Symptom onset—PPCI time, min 187 251 ,0.001
Differences between categorical variables were assessed with x2 test. Differences in continuous variables were assessed with the Student’s t-test if normally distributed. Use of
intra-aortic balloon pump (IABP) defined circulatory support in this study.
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Primary Endpoint
The primary end point was defined as infarct artery
patency according to PHH administration. Secondary end-
points were 30-day mortality and 5-year mortality.
Statistical Analysis
Statistical analysis was performed using SPSS 22.0
(SPSS Inc, Chicago, IL). Categorical variables are shown as
proportions (percentage), and were analyzed using Pearson’s
x2 test. Quantitative variables are expressed as means 6 SD.
A two-sided P-value of 0.05 was considered statistically sig-
nificant. To determine independent predictors of initial IRA
TIMI 2–3 flow, multiple regression analysis using logistic
regression model was performed. The model included age,
sex, cardiogenic shock, radial access, call for help—PPCI
time, symptom onset—PPCI time, previous CABG, Duke
score, and PHH administration. Multiple regression models
were also used to determine independent predictors of 30-day
mortality and 5-year mortality. Graphs and diagrams were
plotted on GraphPad Prism version 6 (GraphPad Software).
RESULTS
In total, 1000 patients were included in this study with
none lost to follow-up. Baseline characteristics for the PHH
group (n = 437) and IHH group (n = 563) (Table 1).
Patients in both groups had similar baseline character-
istics except PHH group were more likely to suffer chronic
lung disease, have a lower Duke Jeopardy score and have
radial access PCI, and less likely to have had previous PCI
treatment. Duke Jeopardy scoring quantifies the amount of
myocardium at risk dependent on coronary artery anatomy.14
Procedural characteristics for the heparin groups are
displayed in Table 2. PHH group had a significantly lower
incidence of circulatory support and cardiogenic shock.
Temporal intervals were significantly increased in IHH
(Table 2).
Interobserver and intraobserver variation of coronary
flow was assessed. A trained medical student assessed TIMI
scoring for the purposes of this study. Intraobserver variabil-
ity was calculated in retrospect, after collating data, and this
showed substantial agreement (kappa . 0.81). Interobserver
variability between a medical student and consultant cardiol-
ogist demonstrated moderate agreement on a continuous scale
of TIMI 0–3 and substantial agreement when TIMI scoring
was grouped (0/1) and (2/3) (Table 3).
Primary and secondary end point analyses are displayed
in Table 4. IRA flow was not significantly different between
the 2 groups. In addition, in-lab and in-hospital event rates
were comparable. Preheparin treatment was associated with
improved 30-day mortality (2.5% PHH vs. 8.3% IHH) and 5-
year mortality (13.0% vs. 21.5%) (Table 4).
Figure 1 shows an unadjusted Kaplan–Meier graph of
survival between PHH group and IHH group (P = 0.0032)
(Fig. 1).
Cox proportional hazard analysis showed PHH is an
independent predictor of lower 30-day, with OR 0.332 (CI
95% 0.168–0.858, P = 0.002) (Table 5), and 5-year mortality
with OR 0.684 (CI 95% 0.489–0.925, P = 0.07) (Table 6).
DISCUSSION
In this retrospective observational study, prehospital
treatment with heparin was associated with significantly
improved long-term survival, after adjustment for important
confounders. However, we did not support our hypothesis
that early administration of heparin would improve early
coronary patency, limiting the extent of myocardial infarc-
tion, and hence improve survival. Although improved flow at





IRA TIMI flow Kappa 0.59 Kappa 0.64
IRA (0/1) or (2/
3)
TIMI flow
Kappa 0.87 Kappa 0.85
Cohen’s kappa coefficient was used to measure interobserver agreement.
TABLE 4. Primary and Secondary End Point Analysis
Prehospital Heparin Group (PHH),
n = 437 IHH Group, n = 563 P
IRA patency
TIMI flow 0–1, n (%) 326 (74.6) 427 (75.8) 0.65
TIMI flow 2–3, n (%) 111 (25.4) 136 (24.2) 0.65
In-lab complications, n (%) 25 (5.7) 33 (5.9) 0.92
In-hospital complications, n (%) 67 (15.3) 81 (14.4) 0.68
Haemorrhagic complications, n (%) 6 (1.4) 5 (0.9) 0.91
Mortality
30-d mortality, n (%) 11 (2.5) 47 (8.3) ,0.001
5-yr mortality, n (%) 57 (13.0) 121 (21.5) ,0.001
Differences between variables were assessed with x2 test.
IRA, infarct artery patency.
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presentation tended to predict improved survival, there was
no observable difference in coronary flow depending on
heparin status. It is uncertain how much of the observed
association can be attributed to a therapeutic effect from
heparin, one that is not apparent in our assessment of
coronary flow, and how much to unmeasured confounding.
Early reperfusion is well established as the most
important goal in the treatment of STEMI patients.
Myocardial damage during STEMI is a time-dependent
process therefore early infarct-related artery patency (defined
as TIMI grade 3) is associated with better clinical outcomes
including survival.15,16 A combination of patient delay, trans-
portation delay, and time needed to establish reperfusion in
the catheter laboratory contribute to total ischemic time for
patients.17 Therefore, any efforts made to promote coronary
reperfusion before PPCI will theoretically decrease myocar-
dial injury and potentially improve patient outcomes.
Previous studies of heparin on vessel patency have
given inconsistent results. There was no benefit seen from
high bolus IV heparin versus low-dose heparin in the HEAP
study.18 In contrast, Zjilstra and colleagues showed improved
vessel patency and improved survival at 30 days in patients
treated with PHH.9 The largest study to date was an analysis
of outcomes in 7000 patients in the TASTE study from
Sweden. This paper described decreased visible thrombus
and increased vessel patency in patients receiving PHH.
There was no association with 30-day survival.19
In these studies coronary flow was assessed by
experienced interventional cardiologists, which may be more
accurate than our results using a trained medical student,
notwithstanding the good accuracy we have shown. Giralt
et al20 showed that vessel patency at presentation is sensitive
to timing of heparin administration relative to symptom onset;
it may be that ischemic preconditioning, preceding aspirin
prescription, and other factors that are difficult to fully
account for in analysis influence the apparent effect on coro-
nary flow from heparin.
It is open to question how much effect could be
expected from the dose of heparin that is currently used.
The Scottish Ambulance Service administers a standard dose
of 5000 international units of IV heparin.21 In a study of 1553
consecutive cases in the Netherlands, this dose was assessed
by activated clotting time measured on arrival in the catheter
laboratory. The ACT was subtherapeutic 82% of all cases,
and subtherapeutic in 92.3% of cases not pretreated with
tirofiban, (which may also prolong the ACT).22 A low ACT
was predicted by increasing weight, and published obesity
prevalence statistics (Scotland 29% vs. Netherlands
19%)23,24 suggests that the Tayside population is not likely
to have a high proportion of patients with a sustained thera-
peutic effect from 5000 units of IV heparin.25
Our study benefits from long follow-up. The associa-
tion between PHH and survival is apparent at 30 days and at 5
years. It is implausible that a single dose of heparin that is
likely to have a significant therapeutic effect for a short time,
in a minority of patients, can be responsible for such a large
observed difference in mortality. The baseline characteristics
and comorbidities (Fig. 1) were strikingly similar given the
difference in survival. Nevertheless, patients who received
PHH had shorter intervals between symptom onset and treat-
ment, and lower incidence of cardiogenic shock. The IHH
patient group was clearly more ill, and probably had more
advanced coronary disease as shown by a higher Duke
Jeopardy score.
FIGURE 1. Kaplan–Meier survival curve shows survival differ-
ences between the 2 groups. Numbers remaining at different
time intervals are shown for both treatment groups.
TABLE 5. Cox Regression Analysis of Mortality at 30-D
Odds Ratio CI 95% P
Age 1.07 1.04–1.09 ,0.001
Male 1.06 0.74–1.40 0.93
Cardiogenic shock 1.79 3.33–10.7 ,0.001
IRA patency 0.82 0.61–1.09 0.42
Radial access 0.53 0.28–0.98 0.04
Pre-hospital heparin 0.33 0.17–0.66 0.02
Call time - PPCI time 0.56 0.01–447.5 0.87
Symptom onset - PPCI time 0.14 0.01–2.34 0.18
Cox regression model used to determine independent predictors of 30-d mortality
post-PPCI. Age, cardiogenic shock, radial access and prehospital heparin administration
were independent predictors in this model.
TABLE 6. Cox-Regression Analysis of Mortality at 5-Years
Odds Ratio CI 95% P
Age 1.07 1.06–1.09 ,0.001
Male 1.06 0.74–1.40 0.93
Cardiogenic shock 3.40 2.23–5.17 ,0.001
IRA patency 0.94 0.82–1.09 0.43
Radial access 0.77 0.50–1.17 0.22
Previous CABG 1.29 0.57–2.96 0.54
Prehospital heparin 0.68 0.49–0.96 0.03
Call time–PPCI time 4.30 0.16–116.5 0.39
Symptom onset–PPCI time 2.21 0.79–6.22 0.13
Cox regression model used to determine independent predictors of 5-year mortality
post-PPCI. Age, cardiogenic shock, and prehospital heparin administration were inde-
pendent predictors in this model.
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It may be that the patients who contact the emergency
services earlier in the clinical course of their MI illustrate a
tendency to interact more favorably with medical services
throughout their lives. We can speculate that they may be
more health literate, more concordant with prescribed ther-
apy, more likely to stop smoking, and better engaged with
cardiac rehabilitation services. Further investigation of the
differences between the groups regarding decision-making
processes when confronted with the symptoms of myocardial
infarction, may be more effective further investigation of the
observed association than a randomized trial of PHH.
In conclusion, PHH treatment has been associated with
improved survival in this, and other observational studies. We
take the view that it is not likely to be a direct effect of
heparin, but that the differences between patient groups are
worthy of further investigation.
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